Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01144949 · ClinicalTrials.gov registry record · Phase 2
Study of Silodosin to Facilitate Passage of Urinary Stones
A Phase 2 study of Kidney Stones and Urolithiasis, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 239
- Enrollment target
- 20
- Study locations
NCT01144949: Completed Phase 2 study of Kidney Stones and Urolithiasis, sponsored by Watson Pharmaceuticals.
NCT01144949 is a Phase 2 study of Kidney Stones and Urolithiasis that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 239 participants, below the 279-participant average among 15 other Kidney Stones trials with a reported enrollment target (14% lower). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01144949, a Phase 2 study of Kidney Stones and Urolithiasis, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 239 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
Primary Outcome
The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes only those stones located in the distal ureter.
Conditions Studied
Interventions
- DRUG placebo
- DRUG silodosin
Study Locations (20)
New York
- Watson Investigational Site - Albany
- Watson Investigational Site - Garden City
- Watson Investigational Site - New York
- Watson Investigational Site - Plainview
- Watson Investigational Site - Syracuse
New Jersey
- Watson Investigational Site - Hackensack
- Watson Investigational Site - Mount Laurel
- Watson Investigational Site - Sewell
- Watson Investigational Site - Voorhees Township
California
- Watson Investigative Site - Mission Hills
- Watson Investigational Site - Murrieta
- Watson Investigational Site - San Diego
Florida
- Watson Investigational Site - Daytona Beach
- Watson Investigational Site - Gainesville
- Watson Investigational Site - Orange City
Alabama
- Watson Investigational Site - Birmingham
Alaska
- Watson Investigational Site - Anchorage
Kansas
- Watson Investigative Site - Overland Park
Missouri
- Watson Investigative Site - North Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 239 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT01144949 record still lists
NCT01144949 is an interventional study that assigns participants to a tested intervention. The registered 239 participants enrollment target is mid-sized for trials with a published cap, below the 279-participant average among 15 other Kidney Stones trials with a reported enrollment target (14% lower).
The record links to 3 conditions, with Kidney Stones appearing as the primary indexed condition, and to 2 interventions - of which placebo is the first listed.
NCT01144949 names 20 study sites across 9 states, led by New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT01144949 about?
NCT01144949 is a clinical study titled "Study of Silodosin to Facilitate Passage of Urinary Stones". The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
What is the current status of trial NCT01144949?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 239 participants. The study started on 2010-06. Estimated completion is 2012-07.
What conditions does trial NCT01144949 study?
This clinical trial studies the following conditions: Kidney Stones, Urolithiasis, Ureteral Calculi.
What interventions are being tested in trial NCT01144949?
The interventions under investigation include: placebo (DRUG), silodosin (DRUG).
Who is sponsoring clinical trial NCT01144949?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01144949 being conducted?
This trial has 20 study locations across Alabama, Alaska, California, Florida, Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Stones
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01144949's enrollment target sits among peer trials
239 4th of 15 higher than 12 of 15 other Kidney Stones trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Kidney Stones trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Endogenous Oxalate Synthesis in Idiopathic Calcium Oxalate Kidney Stone Disease
RECRUITING · NA
-
Evaluation of Eye Gaze Sharing in the Operating Room
RECRUITING · NA
-
Thulium Fiber Laser (TFL) vs Thulio Pulsed Thulium:YAG (p-Tm:YAG)
RECRUITING · NA
-
CaOx Stone Prevention
RECRUITING · Phase 4
-
Eye Gaze Guidance Evaluation in Phantoms
RECRUITING · NA
-
SGLT2i in Kidney Stones
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia